JP6987084B2 - β−カテニン関連疾患又は障害の治療のための組成物及び方法 - Google Patents

β−カテニン関連疾患又は障害の治療のための組成物及び方法 Download PDF

Info

Publication number
JP6987084B2
JP6987084B2 JP2018568165A JP2018568165A JP6987084B2 JP 6987084 B2 JP6987084 B2 JP 6987084B2 JP 2018568165 A JP2018568165 A JP 2018568165A JP 2018568165 A JP2018568165 A JP 2018568165A JP 6987084 B2 JP6987084 B2 JP 6987084B2
Authority
JP
Japan
Prior art keywords
catenin
nucleic acid
pharmaceutical composition
inhibitor molecule
acid inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018568165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512543A5 (enExample
JP2019512543A (ja
Inventor
マーク エイブラムス
シャンティ ガネッシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dicerna Pharmaceuticals Inc
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of JP2019512543A publication Critical patent/JP2019512543A/ja
Publication of JP2019512543A5 publication Critical patent/JP2019512543A5/ja
Priority to JP2021193759A priority Critical patent/JP7321236B2/ja
Application granted granted Critical
Publication of JP6987084B2 publication Critical patent/JP6987084B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018568165A 2016-03-16 2017-03-15 β−カテニン関連疾患又は障害の治療のための組成物及び方法 Expired - Fee Related JP6987084B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021193759A JP7321236B2 (ja) 2016-03-16 2021-11-30 β－カテニン関連疾患又は障害の治療のための組成物及び方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662309449P 2016-03-16 2016-03-16
US62/309,449 2016-03-16
US201662318529P 2016-04-05 2016-04-05
US62/318,529 2016-04-05
US201662365164P 2016-07-21 2016-07-21
US62/365,164 2016-07-21
PCT/US2017/022510 WO2017160983A1 (en) 2016-03-16 2017-03-15 Compositions and methods for the treatment of a beta-catenin-associated disease or disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021193759A Division JP7321236B2 (ja) 2016-03-16 2021-11-30 β－カテニン関連疾患又は障害の治療のための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2019512543A JP2019512543A (ja) 2019-05-16
JP2019512543A5 JP2019512543A5 (enExample) 2019-09-12
JP6987084B2 true JP6987084B2 (ja) 2021-12-22

Family

ID=59850959

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018568165A Expired - Fee Related JP6987084B2 (ja) 2016-03-16 2017-03-15 β−カテニン関連疾患又は障害の治療のための組成物及び方法
JP2021193759A Active JP7321236B2 (ja) 2016-03-16 2021-11-30 β－カテニン関連疾患又は障害の治療のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021193759A Active JP7321236B2 (ja) 2016-03-16 2021-11-30 β－カテニン関連疾患又は障害の治療のための組成物及び方法

Country Status (6)

Country Link
US (3) US10821112B2 (enExample)
EP (1) EP3429598A4 (enExample)
JP (2) JP6987084B2 (enExample)
AU (2) AU2017232496B2 (enExample)
CA (1) CA3017963A1 (enExample)
WO (1) WO2017160983A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017232496B2 (en) * 2016-03-16 2022-11-24 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
JP2021500026A (ja) * 2017-10-18 2021-01-07 ディセルナ ファーマシューティカルズ インコーポレイテッド βカテニン核酸阻害剤分子
US11813280B2 (en) 2018-01-05 2023-11-14 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy
KR20210127917A (ko) * 2018-12-12 2021-10-25 다이서나 파마수이티컬, 인크. 트리루프를 함유하는 이중-가닥의 핵산 억제제 분자
WO2023122316A2 (en) * 2021-12-23 2023-06-29 Aligos Therapeutics, Inc. SPLICE SWITCH OLIGONUCLEOTIDE (SSO) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF
WO2023152351A1 (en) * 2022-02-14 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of liver cancers by disrupting the beta-catenin/tcf-4 binding site located upstream of meg3 in the dlk1/dio3 locus
JP2025536290A (ja) * 2022-10-21 2025-11-05 リカージョン ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路腫瘍抑制因子に突然変異を有する癌の治療
WO2025147555A1 (en) * 2024-01-05 2025-07-10 Recursion Pharmaceuticals, Inc. Rec-4881 (tak-733) for use in treating or preventing colorectal cancer and related diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002256398A2 (en) * 2001-04-30 2002-11-11 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
WO2009029293A2 (en) 2007-03-02 2009-03-05 Mdrna, Inc. Nucleic acid compounds for inhibiting myc gene expression and uses thereof
JP5976643B2 (ja) 2010-07-06 2016-08-24 ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 二本鎖ｒｎａによるベータ−カテニンの特異的阻害に対する方法と組成物
US8518907B2 (en) * 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
US20150073033A1 (en) * 2011-10-31 2015-03-12 Board Of Regents, The University Of Texas System Biomarkers for cancer characterization and treatment
BR112014016870A2 (pt) * 2012-01-09 2017-06-27 Huesken Dieter composições orgânicas para tratar doenças relacionadas com beta-catenina
US9562228B2 (en) * 2012-09-14 2017-02-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of MYC by double-stranded RNA
US10201556B2 (en) * 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
CA2904338C (en) 2013-03-05 2022-07-05 University Of Tennessee Research Foundation Use of imidazole derivatives in combination with a braf inhibitor or mek inhibitor in the treatment of cancer
ES2733929T3 (es) * 2013-07-12 2019-12-03 Piramal Entpr Ltd Una combinación farmacéutica para el tratamiento del melanoma
KR102186363B1 (ko) * 2013-09-06 2020-12-04 삼성전자주식회사 c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물
KR102192591B1 (ko) 2013-09-09 2020-12-18 삼성전자주식회사 c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물
US10111897B2 (en) * 2013-10-03 2018-10-30 Duke University Compositions and methods for treating cancer with JAK2 activity
US9895312B2 (en) 2014-04-08 2018-02-20 Pablo E. Vivas-Mejia Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
AU2017232496B2 (en) * 2016-03-16 2022-11-24 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder

Also Published As

Publication number Publication date
AU2017232496A1 (en) 2018-10-04
AU2023200960A1 (en) 2023-04-27
AU2017232496B2 (en) 2022-11-24
US20210015820A1 (en) 2021-01-21
US11504374B2 (en) 2022-11-22
EP3429598A1 (en) 2019-01-23
JP2019512543A (ja) 2019-05-16
US10821112B2 (en) 2020-11-03
JP7321236B2 (ja) 2023-08-04
CA3017963A1 (en) 2017-09-21
EP3429598A4 (en) 2020-04-01
US20190070180A1 (en) 2019-03-07
WO2017160983A1 (en) 2017-09-21
JP2022033848A (ja) 2022-03-02
US20230190753A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
JP6987084B2 (ja) β−カテニン関連疾患又は障害の治療のための組成物及び方法
US20240124874A1 (en) C/EBP Alpha Short Activating RNA Compositions and Methods of Use
JP6730285B2 (ja) Ｒｎａ干渉組成物及び悪性腫瘍のための方法
CN1703229B (zh) 治疗前列腺和其他癌的组合物和其制备药物的用途
JP2016204365A (ja) Ｂｒａｆ遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物
JP5406024B2 (ja) Ｂｃｌ−ＸＬ特異的ｓｉＮＡを用いる癌治療法
JP2023082028A (ja) Ｓｅｔｄ２を阻害することにより癌を処置する方法
TWI840449B (zh) 用於惡性腫瘤之rna干擾輸送配方及方法
EP3743094B1 (en) Mda-7/il-24 secretory variants and methods of use
WO2017160797A1 (en) Combination therapy with c-myc nucleic acid inhibitors and selective cdk7 inhibitors
JP7525578B2 (ja) Ｃ／ＥＢＰα小分子活性化ＲＮＡ組成物
HK40070347A (en) C/ebp alpha short activating rna compositions and methods of use
HK40018320A (en) C/ebp alpha short activating rna compositions and methods of use
HK40018320B (en) C/ebp alpha short activating rna compositions and methods of use
WO2014148529A1 (ja) 二本鎖核酸分子、ｄｎａ、ベクター、癌細胞増殖抑制剤、及び医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210624

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211130

R150 Certificate of patent or registration of utility model

Ref document number: 6987084

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees